Literature DB >> 11195972

Light chain of botulinum A neurotoxin expressed as an inclusion body from a synthetic gene is catalytically and functionally active.

S A Ahmed1, L A Smith.   

Abstract

Botulinum neurotoxins, the most potent of all toxins, induce lethal neuromuscular paralysis by inhibiting exocytosis at the neuromuscular junction. The light chains (LC) of these dichain neurotoxins are a new class of zinc-endopeptidases that specifically cleave the synaptosomal proteins, SNAP-25, VAMP, or syntaxin at discrete sites. To facilitate the structural and functional characterization of these unique endopeptidases, we constructed a synthetic gene for the LC of the botulinum neurotoxin serotype A (BoNT/A), overexpressed it in Escherichia coli, and purified the gene product from inclusion bodies. Our procedure can provide 1.1 g of the LC from 1 L of culture. The LC product was stable in solution at 4 degrees C for at least 6 months. This rBoNT/A LC was proteolytically active, specifically cleaving the Glu-Arg bond in a 17-residue synthetic peptide of SNAP-25, the reported cleavage site of BoNT/A. Its calculated catalytic efficiency kcat/Km was higher than that reported for the native BoNT/A dichain. Treating the rBoNT/A LC with mercuric compounds completely abolished its activity, most probably by modifying the cysteine-164 residue located in the vicinity of the active site. About 70% activity of the LC was restored by adding Zn2+ to a Zn2+-free, apo-LC preparation. The LC was nontoxic to mice and failed to elicit neutralizing epitope(s) when the animals were vaccinated with this protein. In addition, injecting rBoNT/A LC into sea urchin eggs inhibited exocytosis-dependent plasma membrane resealing. For the first time, results of our study make available a large amount of the biologically active toxin fragment in a soluble and stable form.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11195972     DOI: 10.1023/a:1026549431380

Source DB:  PubMed          Journal:  J Protein Chem        ISSN: 0277-8033


  14 in total

1.  Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.

Authors:  Daniel M Held; Amy C Shurtleff; Scott Fields; Christopher Green; Julie Fong; Russell G A Jones; Dorothea Sesardic; Roland Buelow; Rae Lyn Burke
Journal:  Clin Vaccine Immunol       Date:  2010-04-21

2.  Metal Ions Effectively Ablate the Action of Botulinum Neurotoxin A.

Authors:  Paul T Bremer; Sabine Pellett; James P Carolan; William H Tepp; Lisa M Eubanks; Karen N Allen; Eric A Johnson; Kim D Janda
Journal:  J Am Chem Soc       Date:  2017-05-19       Impact factor: 15.419

3.  Inhibition of catalytic activities of botulinum neurotoxin light chains of serotypes A, B and E by acetate, sulfate and calcium.

Authors:  Rahman M Mizanur; John Gorbet; S Swaminathan; S Ashraf Ahmed
Journal:  Int J Biochem Mol Biol       Date:  2012-09-25

4.  Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.

Authors:  R Levy; C M Forsyth; S L LaPorte; I N Geren; L A Smith; J D Marks
Journal:  J Mol Biol       Date:  2006-10-03       Impact factor: 5.469

5.  Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity.

Authors:  Martha Hale; George Oyler; Subramanyam Swaminathan; S Ashraf Ahmed
Journal:  J Biol Chem       Date:  2010-10-20       Impact factor: 5.157

6.  Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.

Authors:  Nizamettin Gul; Leonard A Smith; S Ashraf Ahmed
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

7.  Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity.

Authors:  S Ashraf Ahmed; Mark A Olson; Matthew L Ludivico; Janice Gilsdorf; Leonard A Smith
Journal:  Protein J       Date:  2008-04       Impact factor: 2.371

8.  The C-terminus of Botulinum A Protease Has Profound and Unanticipated Kinetic Consequences Upon the Catalytic Cleft.

Authors:  Peter Silhár; Matthew A Lardy; Mark S Hixon; Charles B Shoemaker; Joseph T Barbieri; Anjali K Struss; Jenny M Lively; Sacha Javor; Kim D Janda
Journal:  ACS Med Chem Lett       Date:  2012-12-23       Impact factor: 4.345

9.  Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery.

Authors:  Philip A Band; Steven Blais; Thomas A Neubert; Timothy J Cardozo; Konstantin Ichtchenko
Journal:  Protein Expr Purif       Date:  2010-01-04       Impact factor: 1.650

10.  Use of a recombinant fluorescent substrate with cleavage sites for all botulinum neurotoxins in high-throughput screening of natural product extracts for inhibitors of serotypes A, B, and E.

Authors:  Harry B Hines; Alexander D Kim; Robert G Stafford; Shirin S Badie; Ernst E Brueggeman; David J Newman; James J Schmidt
Journal:  Appl Environ Microbiol       Date:  2007-12-14       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.